Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer

Irene L. Wapnir, Stefan Aebi, Shari Gelber, Stewart J. Anderson, I. Láng, André Robidoux, Eleftherios P. Mamounas, Norman Wolmark

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: The utility of chemotherapy for women who experience a locoregional recurrence after primary treatment of early breast cancer remains an open question. An international collaborative trial is being conducted by the Breast International Group (BIG), the International Breast Cancer Study Group (IBCSG), and the National Surgical Adjuvant Breast and Bowel Project (NSABP) to determine the effectiveness of cytotoxic therapy for these patients, either alone or in addition to selective use of hormonal therapy and trastuzumab. Methods: The trial population includes women who have had a previous diagnosis of invasive breast cancer treated by mastectomy or breast-conserving surgery, but subsequently develop an isolated local and/or regional ipsilateral invasive recurrence. Excision of all macroscopic tumor without evidence of systemic disease is required for study entry. Patients are randomized to receive chemotherapy or no chemotherapy; type of chemotherapy is not protocol-specified. Radiation, hormonal therapy, and trastuzumab are given as appropriate. The primary endpoint is disease-free survival (DFS). Quality-of-life measurements are collected at baseline, and then at 9 and 12 months. The accrual goal is 977 patients. Results: This report describes the characteristics of the first 99 patients. Sites of recurrence at study entry were: breast (56%), mastectomy scar/chest wall (35%), and regional lymph nodes (9%). Two-thirds of patients have estrogen-receptor-positive recurrences. Conclusion: This is the only trial actively investigating the question of "adjuvant" chemotherapy in locally recurrent breast cancer. The case mix of accrual to date indicates a broad representation of this patient population.

Original languageEnglish
Pages (from-to)3227-3231
Number of pages5
JournalAnnals of Surgical Oncology
Volume15
Issue number11
DOIs
Publication statusPublished - Nov 2008

Fingerprint

Breast
Breast Neoplasms
Recurrence
Drug Therapy
Mastectomy
Therapeutics
Segmental Mastectomy
Diagnosis-Related Groups
Thoracic Wall
Adjuvant Chemotherapy
Estrogen Receptors
Population
Disease-Free Survival
Cicatrix
Radiotherapy
Lymph Nodes
Quality of Life
Neoplasms
Trastuzumab

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer. / Wapnir, Irene L.; Aebi, Stefan; Gelber, Shari; Anderson, Stewart J.; Láng, I.; Robidoux, André; Mamounas, Eleftherios P.; Wolmark, Norman.

In: Annals of Surgical Oncology, Vol. 15, No. 11, 11.2008, p. 3227-3231.

Research output: Contribution to journalArticle

Wapnir, Irene L. ; Aebi, Stefan ; Gelber, Shari ; Anderson, Stewart J. ; Láng, I. ; Robidoux, André ; Mamounas, Eleftherios P. ; Wolmark, Norman. / Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer. In: Annals of Surgical Oncology. 2008 ; Vol. 15, No. 11. pp. 3227-3231.
@article{3d33222831c548969ee30d0ed7de52e4,
title = "Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer",
abstract = "Background: The utility of chemotherapy for women who experience a locoregional recurrence after primary treatment of early breast cancer remains an open question. An international collaborative trial is being conducted by the Breast International Group (BIG), the International Breast Cancer Study Group (IBCSG), and the National Surgical Adjuvant Breast and Bowel Project (NSABP) to determine the effectiveness of cytotoxic therapy for these patients, either alone or in addition to selective use of hormonal therapy and trastuzumab. Methods: The trial population includes women who have had a previous diagnosis of invasive breast cancer treated by mastectomy or breast-conserving surgery, but subsequently develop an isolated local and/or regional ipsilateral invasive recurrence. Excision of all macroscopic tumor without evidence of systemic disease is required for study entry. Patients are randomized to receive chemotherapy or no chemotherapy; type of chemotherapy is not protocol-specified. Radiation, hormonal therapy, and trastuzumab are given as appropriate. The primary endpoint is disease-free survival (DFS). Quality-of-life measurements are collected at baseline, and then at 9 and 12 months. The accrual goal is 977 patients. Results: This report describes the characteristics of the first 99 patients. Sites of recurrence at study entry were: breast (56{\%}), mastectomy scar/chest wall (35{\%}), and regional lymph nodes (9{\%}). Two-thirds of patients have estrogen-receptor-positive recurrences. Conclusion: This is the only trial actively investigating the question of {"}adjuvant{"} chemotherapy in locally recurrent breast cancer. The case mix of accrual to date indicates a broad representation of this patient population.",
author = "Wapnir, {Irene L.} and Stefan Aebi and Shari Gelber and Anderson, {Stewart J.} and I. L{\'a}ng and Andr{\'e} Robidoux and Mamounas, {Eleftherios P.} and Norman Wolmark",
year = "2008",
month = "11",
doi = "10.1245/s10434-008-0129-2",
language = "English",
volume = "15",
pages = "3227--3231",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer

AU - Wapnir, Irene L.

AU - Aebi, Stefan

AU - Gelber, Shari

AU - Anderson, Stewart J.

AU - Láng, I.

AU - Robidoux, André

AU - Mamounas, Eleftherios P.

AU - Wolmark, Norman

PY - 2008/11

Y1 - 2008/11

N2 - Background: The utility of chemotherapy for women who experience a locoregional recurrence after primary treatment of early breast cancer remains an open question. An international collaborative trial is being conducted by the Breast International Group (BIG), the International Breast Cancer Study Group (IBCSG), and the National Surgical Adjuvant Breast and Bowel Project (NSABP) to determine the effectiveness of cytotoxic therapy for these patients, either alone or in addition to selective use of hormonal therapy and trastuzumab. Methods: The trial population includes women who have had a previous diagnosis of invasive breast cancer treated by mastectomy or breast-conserving surgery, but subsequently develop an isolated local and/or regional ipsilateral invasive recurrence. Excision of all macroscopic tumor without evidence of systemic disease is required for study entry. Patients are randomized to receive chemotherapy or no chemotherapy; type of chemotherapy is not protocol-specified. Radiation, hormonal therapy, and trastuzumab are given as appropriate. The primary endpoint is disease-free survival (DFS). Quality-of-life measurements are collected at baseline, and then at 9 and 12 months. The accrual goal is 977 patients. Results: This report describes the characteristics of the first 99 patients. Sites of recurrence at study entry were: breast (56%), mastectomy scar/chest wall (35%), and regional lymph nodes (9%). Two-thirds of patients have estrogen-receptor-positive recurrences. Conclusion: This is the only trial actively investigating the question of "adjuvant" chemotherapy in locally recurrent breast cancer. The case mix of accrual to date indicates a broad representation of this patient population.

AB - Background: The utility of chemotherapy for women who experience a locoregional recurrence after primary treatment of early breast cancer remains an open question. An international collaborative trial is being conducted by the Breast International Group (BIG), the International Breast Cancer Study Group (IBCSG), and the National Surgical Adjuvant Breast and Bowel Project (NSABP) to determine the effectiveness of cytotoxic therapy for these patients, either alone or in addition to selective use of hormonal therapy and trastuzumab. Methods: The trial population includes women who have had a previous diagnosis of invasive breast cancer treated by mastectomy or breast-conserving surgery, but subsequently develop an isolated local and/or regional ipsilateral invasive recurrence. Excision of all macroscopic tumor without evidence of systemic disease is required for study entry. Patients are randomized to receive chemotherapy or no chemotherapy; type of chemotherapy is not protocol-specified. Radiation, hormonal therapy, and trastuzumab are given as appropriate. The primary endpoint is disease-free survival (DFS). Quality-of-life measurements are collected at baseline, and then at 9 and 12 months. The accrual goal is 977 patients. Results: This report describes the characteristics of the first 99 patients. Sites of recurrence at study entry were: breast (56%), mastectomy scar/chest wall (35%), and regional lymph nodes (9%). Two-thirds of patients have estrogen-receptor-positive recurrences. Conclusion: This is the only trial actively investigating the question of "adjuvant" chemotherapy in locally recurrent breast cancer. The case mix of accrual to date indicates a broad representation of this patient population.

UR - http://www.scopus.com/inward/record.url?scp=55149086548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55149086548&partnerID=8YFLogxK

U2 - 10.1245/s10434-008-0129-2

DO - 10.1245/s10434-008-0129-2

M3 - Article

C2 - 18784962

AN - SCOPUS:55149086548

VL - 15

SP - 3227

EP - 3231

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 11

ER -